Newron Pharmaceuticals - Evenamide validation underway

Newron is developing evenamide (30mg twice per day) as an add-on to treat poorly managed and refractory schizophrenia. A potentially pivotal Phase II/III study is underway and could report by Q422. Newron hopes to partner evenamide for larger indications while selling the product directly to the targeted clozapine-resistant market. [mehr]

Weiterlesen: https://ift.tt/3ug2eiy